Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
PDUFA target action date set for December 20, 2024THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.…